Clinical Trial Update: Post-Authorization Safety Study for Assessment of Pregnancy Outcomes in Patients Treated With Mayzent

View source ↗

Summary

Post-authorization safety study assessing pregnancy outcomes in patients treated with Mayzent (fingolimod) for multiple sclerosis. The study is currently recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• MAYZENT (siponimod)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Multiple Sclerosis | Status: RECRUITING